JAKARTA. PT Diagnos Laboratorium Utama Tbk (DGNS) will acquire 97.97% of the shares of Asa Ren Pte. Ltd, an AI-based DNA data company registered in Singapore, with a transaction value estimated at IDR 357.89 billion.

The acquisition of Asa Ren will be carried out by DGNS through an inbreng of 88.17% or 612,900 shares, as well as the purchase of 9.80% or 68,100 ordinary shares owned by Asa Ren's shareholders. This corporate action will be finalized after each party has completed their respective obligations in accordance with the agreed agreement.

DGNS management said the acquisition of Asa Ren is part of the company's business development and service improvement. The services provided by Asa Ren are believed to bring new business opportunities for the company.

"The Company believes that the synergy between the Company and Asa Ren will not only strengthen the Company's position in the healthcare industry, but will also provide significant benefits to the wider community," wrote DGNS Management.

Related to the acquisition plan, DGNS will also issue 921 million new shares, with a rights issue scheme. Some of these new shares will later be transferred to Asa Ren shareholders in the form of an inbreng.

According to idnfinancials.com data, DGNS recently suffered a loss of IDR 13.66 billion in the 2023 financial year. This is the first loss experienced by the company since it was listed as a member of the Indonesia Stock Exchange.

Meanwhile, Asa Ren also suffered a loss of SG$2.76 million in the 2023 financial year. In the previous year, the company also suffered a loss of SG$1.97 million. (KR/LM)